Glaxo presses on to find the next critical antibiotic
Despite the rise of superbugs, big pharma has largely exited antibiotic research because of low payoff
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
London
IN A cramped lab in rural Penn-sylvania, surrounded by technicians in obligatory white lab coats and fume hoods leaking an occasional acrid smell, Neil Pearson holds up a plastic model of a chemical compound that resembles a spidery piece of Lego.
Mr Pearson, a 54-year-old chemist and senior fellow at British pharmaceutical giant GlaxoSmithkline plc, explains how he spent more than a decade tinkering with chemical compounds before engineering a molecule that may yield the industry's first truly new antibiotic in 30 years to fight the rise of superbugs that risk killing an extra 10 million people every year by 2050.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Singaporeans can now buy record amount of yen per Singdollar
